• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer" [Canc. Lett. 438 (2018, Dec 1) 165-173].

作者信息

Lin Chang-Ching, Lo Miao-Chia, Moody Rebecca, Jiang Hui, Harouaka Ramdane, Stevers Nicholas, Tinsley Samantha, Gasparyan Mari, Wicha Max, Sun Duxin

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.

Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA; Chemical Biology Program, University of Michigan, Ann Arbor, MI, 48109, USA.

出版信息

Cancer Lett. 2020 Jun 28;480:51. doi: 10.1016/j.canlet.2020.01.013. Epub 2020 Mar 27.

DOI:10.1016/j.canlet.2020.01.013
PMID:32229161
Abstract
摘要

相似文献

1
Corrigendum to "Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer" [Canc. Lett. 438 (2018, Dec 1) 165-173].《“靶向低密度脂蛋白受体相关蛋白8抑制三阴性乳腺癌中的乳腺癌干细胞”的勘误》[《癌症快报》438卷（2018年12月1日）165 - 173页]
Cancer Lett. 2020 Jun 28;480:51. doi: 10.1016/j.canlet.2020.01.013. Epub 2020 Mar 27.
2
Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.靶向 LRP8 抑制三阴性乳腺癌中的乳腺癌干细胞。
Cancer Lett. 2018 Dec 1;438:165-173. doi: 10.1016/j.canlet.2018.09.022. Epub 2018 Sep 15.
3
Corrigendum to "Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway" [Canc. Lett. (2023) 216142].《“发现YH677作为一种癌症干性抑制剂，通过调节TGFβ信号通路抑制三阴性乳腺癌的生长和转移”的勘误》[《癌症通讯》（2023年）216142]
Cancer Lett. 2023 Jul 28;567:216195. doi: 10.1016/j.canlet.2023.216195. Epub 2023 May 6.
4
Corrigendum to "Targeting autophagy in cancer stem cells as an anticancer therapy" [Canc. Lett. 393 (2017) 33-39].
Cancer Lett. 2018 Mar 1;416:149. doi: 10.1016/j.canlet.2017.12.027. Epub 2018 Jan 4.
5
Corrigendum to "MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer", [Canc. Lett. 399 (2017) 53-63].
Cancer Lett. 2018 Apr 28;420:260. doi: 10.1016/j.canlet.2018.01.073. Epub 2018 Feb 21.
6
Corrigendum to "Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3" [Canc. Lett. 498 (2021) 130-141].《“长链非编码RNA LINC00657通过吸附miR-20a-5p和靶向RUNX3抑制宫颈癌发展”的勘误》[《癌症快报》498 (2021) 130 - 141]
Cancer Lett. 2021 Jun 28;508:73-75. doi: 10.1016/j.canlet.2021.03.005. Epub 2021 Mar 30.
7
Corrigendum to 'GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft' [Canc. Lett. 330 (2013) 22-32].《“GANT-61抑制体外培养及NOD/SCID/IL2Rγ基因敲除小鼠异种移植模型中胰腺癌干细胞生长”的勘误》[《癌症快报》330 (2013) 22 - 32]
Cancer Lett. 2021 Dec 1;522:282. doi: 10.1016/j.canlet.2021.07.028. Epub 2021 Sep 24.
8
Corrigendum to "Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells" [Canc. Lett. 412 (2018) 297-307].对“人参炔醇，一种天然的热休克蛋白90抑制剂，有效靶向肺癌干细胞和非干细胞”[《癌症快报》412（2018）297 - 307]的勘误
Cancer Lett. 2018 Jun 28;424:136. doi: 10.1016/j.canlet.2018.03.023. Epub 2018 Mar 21.
9
Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling" [Canc. Lett. 471 (2020) 135-146].《“2'-羟基黄烷酮通过抑制STAT3信号通路抑制胰腺癌细胞的进展并增强EGFR抑制剂的化疗敏感性”的勘误》[癌症通讯471 (2020) 135 - 146]
Cancer Lett. 2022 Nov 28;549:215913. doi: 10.1016/j.canlet.2022.215913. Epub 2022 Sep 22.
10
Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].《“Rab8A通过增加原肌球蛋白相关激酶B的表面表达促进乳腺癌进展”的更正》[《癌症快报》535 (2022) 215629]
Cancer Lett. 2022 Jul 28;539:215701. doi: 10.1016/j.canlet.2022.215701. Epub 2022 May 6.

引用本文的文献

1
The regulation of LRPs by miRNAs in cancer: influencing cancer characteristics and responses to treatment.微小RNA在癌症中对低密度脂蛋白受体相关蛋白的调控：影响癌症特征及对治疗的反应
Cancer Cell Int. 2025 May 17;25(1):182. doi: 10.1186/s12935-025-03804-z.
2
miR-362-3p suppresses ovarian cancer by inhibiting LRP8.微小RNA-362-3p通过抑制低密度脂蛋白受体相关蛋白8来抑制卵巢癌。
Transl Oncol. 2022 Jan;15(1):101284. doi: 10.1016/j.tranon.2021.101284. Epub 2021 Nov 26.